ERBB2 and neoplasm: 18F-FBEM-ZHER2:342-Affibody seems to represent a noninvasive option for obtaining real-time information on changes in HER2 expression that facilitates patient selection for anti-HER2 therapy, such as 17-DMAG or trastuzumab treatment, and would result in optimal dose adjustment and treatment schedule for individual patients, as well as in the prediction of tumor response [16–18].